Small Pharma Inc.

TSX-V: DMT

Company Logo

Company Overview

Small Pharma is a neuropharmaceutical company specialised in IP led development of novel treatments for mental health conditions, with a focus on depression. Small Pharma initiated a clinical program into DMT-assisted therapy in February 2021. This program includes a Phase I/IIa trial on their lead candidate alongside development of a robust pipeline of proprietary preclinical assets.

Current Management Team


Peter Rands
Chief Executive Officer

Marie Layzell
Chief Operating Officer

Carol Routledge
Chief Medical and Scientific Officer

George Tziras
Chief Business Officer

Daniel Steel
Chief Financial Officer

Current Board of Directors


Lyne Fortin
Independent Director

Michael Wolfe
Independent Director

Peter Rands
Director

Marie Layzell
Director

George Tziras
Director

Financial Highlights

$33,660

Revenue (ttm)

$45,000

Gross Profit (ttm)

-$0.17

Diluted EPS (ttm)

Management Team

Mr. Peter David Rands
CEO & Director

Mr. David Steel
Chief Financial Officer

Ms. Marie Claire Layzell
COO, Head of CMC & Director

Dr. Carol Routledge
Chief Scientific & Medical Officer

Mr. George Tziras
Non-Exec. Director & Chief Bus. Officer

Ms. Nina Kumari
Head of Bus. Devel.

Mr. Richard M. Kimel
Corp. Sec.

Mr. Jim Rennie
Director of Devel. and Member of Scientific & Advisory Board

Sign Up for Alerts

Receive an email alert every time a company announces a merger, capital raise or files for an IPO.

Company Profile

Website

Twitter

Presentation

Key Highlights

Market Capitalization
$0

Shares Outstanding
0

Shares Short (% of Float)
149,837 (0%)

Insider Ownership
31%